Through the acquisition, Pfizer has gained exclusive North American commercialization rights to the FDA approved Quillivant XR.
Quillivant XR (methylphenidate hydrochloride) extended-release oral suspension is indicated to treat attention deficit hyperactivity disorder.
The once daily oral medication will be made available in the US pharmacies in January 2013.
Pfizer revealed its intention to acquire NextWave in a deal valued at $700m in October 2012.